Continental Grain invested in a series D round that boosted the RNA technology provider's overall funding to $214m as it allocates more resources to vaccine work.

US-based agricultural and life sciences technology provider GreenLight Biosciences secured $102m yesterday in a series D round that included grain trading firm Continental Grain. Venture capital firm Morningside Ventures led the oversubscribed round, which also featured S2G Ventures, Cormorant Asset Management, Fall Line Capital, Tao Capital Partners, Baird Capital, MLS Capital, Lupa Systems and Lewis…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.